ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Roche and Jnana sign SLC transporter pact

by Lisa M. Jarvis
July 25, 2020 | APPEARED IN VOLUME 98, ISSUE 29

 

Roche will pay Boston-based Jnana Therapeutics $40 million up front as part of a drug discovery pact that spans targets relevant in immunology and neuroscience. Stuart Schreiber and Ramnik Xavier, scientists at Broad Institute of MIT and Harvard, founded Jnana in 2017 to develop small molecules that target members of a family of 450 proteins, called solute carriers (SLC), that shuttle metabolites in and out of cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment